Amarin Co. plc (NASDAQ:AMRN) General Counsel Joseph T. Kennedy sold 44,857 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $3.73, for a total transaction of $167,316.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Amarin Co. plc (AMRN) traded down $0.04 during trading hours on Friday, reaching $3.76. 3,208,393 shares of the company traded hands, compared to its average volume of 2,620,000. The company has a market cap of $1,020.00, a P/E ratio of -13.91 and a beta of 0.50. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63. Amarin Co. plc has a fifty-two week low of $2.85 and a fifty-two week high of $4.60.
Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million during the quarter, compared to the consensus estimate of $45.85 million. During the same period in the previous year, the company earned ($0.08) EPS. Amarin’s revenue for the quarter was up 45.4% on a year-over-year basis. equities analysts predict that Amarin Co. plc will post -0.22 earnings per share for the current fiscal year.
Several brokerages recently commented on AMRN. Cantor Fitzgerald set a $10.00 price objective on shares of Amarin and gave the company a “buy” rating in a research note on Wednesday, December 6th. ValuEngine raised shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. BidaskClub downgraded shares of Amarin from a “hold” rating to a “sell” rating in a research note on Wednesday. Jefferies Group reissued a “buy” rating on shares of Amarin in a research note on Wednesday, October 11th. Finally, Zacks Investment Research downgraded shares of Amarin from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.75.
Amarin Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.